Efficacy and Feasibility of Indocyanine Green for Mapping Lymph Nodes in Advanced Gastric Cancer Patients Undergoing Laparoscopic Distal Gastrectomy

2020 ◽  
Vol 24 (10) ◽  
pp. 2306-2309
Author(s):  
Shuai Ma ◽  
Yue-Ming Zhang ◽  
Li-Zhou Dou ◽  
Hao Liu ◽  
Fu-Hai Ma ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Lymph Nodes ◽  
Indocyanine Green ◽  
Advanced Gastric Cancer ◽  
Cancer Patients ◽  
Distal Gastrectomy ◽  
Laparoscopic Distal Gastrectomy ◽  
Gastric Cancer Patients

scholarly journals A homogenized approach to classify advanced gastric cancer patients with limited and adequate number of pathologically examined lymph nodes

2019 ◽  
Vol 39 (1) ◽  
pp. 32 ◽  
Author(s):  
Sharvesh Raj Seeruttun ◽  
Lipu Xu ◽  
Fangwei Wang ◽  
Xiaodong Yi ◽  
Cheng Fang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Lymph Nodes ◽  
Advanced Gastric Cancer ◽  
Cancer Patients ◽  
Adequate Number ◽  
Gastric Cancer Patients

scholarly journals Effect of single-incision laparoscopic distal gastrectomy guided by ERAS and the influence on immune function

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Junfeng Zhou ◽  
Sheng Lin ◽  
Sida Sun ◽  
Chengying Zheng ◽  
Jiaxing Wang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Immune Function ◽  
Cancer Patients ◽  
Distal Gastrectomy ◽  
Single Incision ◽  
Laparoscopic Distal Gastrectomy ◽  
Significant Difference ◽  
Group A ◽  
Group B ◽  
Gastric Cancer Patients

Abstract Background To evaluate the immune function of gastric cancer patients after single-incision laparoscopic distal gastrectomy (SIDG) or multiport laparoscopic distal gastrectomy (MLDG) guided by enhanced recovery after surgery (ERAS). Methods A retrospective cohort study was performed on 120 patients who underwent laparoscopic distal gastrectomy for gastric cancer. The patients were divided into two groups according to operation method: group A (MLDG) and group B (SIDG), both guided by ERAS concept. The indicators reflecting immune function and inflammation, such as CD3+, CD4+, CD8+ and NK cell count, CD4+/CD8+ cell ratios, IgA, IgM and IgG levels, C-reactive protein (CRP), total lymphocyte count (TLC) and neutrophil-to-lymphocyte ratio (NLR) were tested 3 days and 7 days after surgery. Results The skin incision length of patients in group B was significantly shorter than that in group A, but the operation time was significantly longer in group B than that in group A (P < 0.05). There were no significant differences in preoperative CD3+, CD4+, CD8+, natural killer (NK) cells, CD4+/CD8+, IgA, IgM and IgG levels between two groups (P < 0.05). Three days after surgery, the immune function indices were decreased in both groups, but with no significant difference between two groups (P > 0.05). On the 7th day after surgery, the immune indexes of both groups recovered somewhat, approaching the preoperative level (P > 0.05). Inflammation indexes increased 3 days after surgery and decreased 7 days after surgery in both groups, among them the CRP level in group A was higher than that in group B (P < 0.05). The 3-year survival rate were 96.7% in group A and 91.7% in group B, respectively, with no statistically significant difference. Conclusion Compared with MLDG guided by ERAS, SIDG under the guidance of the ERAS concept has better cosmetic effect and similar effect on immune function of gastric cancer patients.

scholarly journals Reduced-port laparoscopic distal gastrectomy in obese gastric cancer patients

PLoS ONE ◽  
2021 ◽  
Vol 16 (8) ◽  
pp. e0255855
Author(s):  
Dong Yeon Kang ◽  
Ho Goon Kim ◽  
Dong Yi Kim
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Surgical Outcomes ◽  
Distal Gastrectomy ◽  
Laparoscopic Distal Gastrectomy ◽  
Obese Patients ◽  
Short Term ◽  
Significant Difference ◽  
Reduced Port ◽  
Gastric Cancer Patients

Background Reduced-port laparoscopic gastrectomy is currently widely performed for patients with gastric cancer. However, its safety in obese patients has not yet been verified. This is the first study on reduced-port laparoscopic distal gastrectomy (RpLDG) in obese patients with gastric cancer. This study aimed to evaluate the short-term surgical outcomes and investigate the feasibility and safety of RpLDG in obese patients with gastric carcinoma. Material and methods A total of 271 gastric cancer patients who underwent RpLDG at our institution were divided into two groups: non-obese [body mass index (BMI) <30 kg/m2, n = 251; NOG] and obese (BMI ≥30 kg/m2, n = 20; OG). The mean age of the enrolled patients was 64.8 ± 11.4 years, with 72.0% being men and 28.0% women. Operative details and short-term surgical outcomes, including hospital course and postoperative complications, were compared by retrospectively reviewing the medical records. Results No significant difference in operation time was found between the NOG and OG (205.9 ± 40.0 vs. 211.3 ± 37.3 minutes, P = 0.563). Other operative outcomes in the OG, including estimated blood loss (54.1 ± 86.1 vs. 54.0 ± 39.0 mL, P = 0.995) and retrieved lymph nodes (36.2 ± 16.4 vs. 35.5 ± 18.2, P = 0.875), were not inferior to those in the NOG. There were also no statistical differences in short-term surgical outcomes, including the incidence of surgical complications (13.9% vs. 10.0%, P = 1). Conclusion RpLDG can be performed safely in obese gastric cancer patients by an experienced surgeon. It should be considered a feasible alternative to conventional port distal gastrectomy.

Sign in / Sign up

Export Citation Format

Share Document